
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Pharmaxis Ltd is a drug manufacturers—general business based in Australia. Pharmaxis shares (PXS) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Pharmaxis has a trailing 12-month revenue of around $12.6 million..
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.053 - $0.285 |
---|---|
50-day moving average | $0.0861 |
200-day moving average | $0.0878 |
Target price | $0.52 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.053 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.094 on 2020-10-22
1 week (2021-01-15) | -4.08% |
---|---|
1 month (2020-12-23) | 11.90% |
3 months (2020-10-23) | 6.82% |
6 months (2020-07-23) | 11.90% |
1 year (2020-01-23) | -24.80% |
---|---|
2 years (2019-01-23) | -64.53% |
3 years (2018-01-23) | -63.85% |
5 years (2016-01-22) | -71.08% |
Revenue TTM | $12.6 million |
---|---|
Gross profit TTM | $11.2 million |
Return on assets TTM | -22.53% |
Return on equity TTM | -171.66% |
Profit margin | -110.53% |
Book value | 0.004 |
Market capitalisation | $36 million |
TTM: trailing 12 months
We're not expecting Pharmaxis to pay a dividend over the next 12 months.
Over the last 12 months, Pharmaxis 's shares have ranged in value from as little as $0.053 up to $0.285. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Pharmaxis 's is 0.508. This would suggest that Pharmaxis 's shares are less volatile than average (for this exchange).
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
From the best overall face moisturiser for dry skin to the best body moisturiser, hand moisturiser and tinted moisturiser for dry skin, these are the best 7 moisturisers for dry skin you can buy in Australia right now.
From the best RC plane for beginners to the top model for aerial photography, these are the six best RC planes in Australia right now.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.